Abstract: A method of treating living tissue includes applying to living tissue a biocompatible adhesive composition containing at least one alkyl ester cyanoacrylate monomer and a polymerization initiator or accelerator, wherein the polymerization initiator or accelerator is a quaternary amine.

Abstract: The invention relates to a transparent or translucent cosmetic emulsion comprising an aqueous phase, a fatty phase and a surfactant, the said fatty phase containing a miscible mixture of at least one cosmetic oil and of at least one volatile fluoro compound, the latter compound being present in a proportion such that the refractive index of the fatty phase is equal to ±0.05 of that of the aqueous phase. The invention also relates to the process for preparing the emulsion. Use of the emulsion in skincare, hair conditioning and antisun protection and/or artificial tanning.

Abstract: A hair dye composition containing at least one of the following compounds: or analogues thereof; and a method for dyeing hair which comprises a step of applying to the hair the hair dye composition is used. The dye composition of the invention exhibits excellent spreadability, applicability, level-dyeing property and shampoo resistance.

Abstract: The invention concerns cosmetic compositions containing, in a cosmetically acceptable medium, as thickening system: (A) at least a non-ionic associative polyurethane and (B) at least a non-ionic polymer comprising at least a fatty chain.

Abstract: Optically-activated fixed particles for use in cosmetic, toiletries, or pharmaceutical preparations. The optically-activated fixed particles include a plurality of substrate particles and a fluorescent compound fixed to each of the plurality of substrate particles to form integral units in the form of optically-activated fixed particles for reducing the visual perception of skin imperfections, including cellulite, shadows, skin discolorations, wrinkles, and mild scars. Each of the optically-activated fixed particles are optionally encapsulated with a transparent or translucent coating.

Abstract: Paclitaxel is provided in a porous matrix form, which allows the drug to be formulated without Cremophor and administered as a bolus. The paclitaxel matrices preferably are made using a process that includes (i) dissolving paclitaxel in a volatile solvent to form a paclitaxel solution, (ii) combining at least one pore forming agent with the paclitaxel solution to form an emulsion, suspension, or second solution, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of paclitaxel. The pore forming agent can be either a volatile liquid that is immiscible with the paclitaxel solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent.

Abstract: A swallowable, solid dose form composition for treating upper gastrointestinal tract distress containing bismuth subsalicylate, carbonate or bicarbonate salt, disintegrating agent, anionic or nonionic surfactant, and microcrystalline cellulose is described.

Abstract: A wiping article is provided which includes an effervescent cleanser composition held within a pouch formed from a first and second substrate sheet. At least one of the substrate sheets must be water permeable. The effervescent composition is an intimate mixture of an acid material such as citric acid and an alkaline material such as sodium bicarbonate. Water contact causes the combination to effervesce. A dry surfactant such as sodium cocoyl isethionate in contact with the water and effervescing carbon dioxide results in a highly pleasant sudsing system. Skin benefit agents may be included within the composition. The effervescent action may improve deposition of the skin benefit agents onto the skin.

Abstract: The invention relates to a method for the treatment of the skin around the eyes of a mammal, in particular a method for reducing the puffiness of and the appearance of dark circles on the skin under the eyes. The method comprises topically applying to the affected skin area a composition comprising an effective amount of at least one alkanolamine having the following general formula: wherein X, Y and Z are selected from the group consisting of hydrogen, C1-C3 alkyl group, C2-C4 alkanol group, wherein at least one of X, Y or Z is a C2-C4 alkanol group bearing at least one hydroxyl group and optionally at least one carboxyl group.

Abstract: A preservative system comprising iodopropynyl butyl carbamate and phenoxyethanol at a weight ratio of iodopropynyl butyl carbamate to phenoxyethanol within the range of about 1:90 to about 1:400 shows a broad anti-microbial effect and can permit use of the preservative system at a low level in end use products such as personal care products.

Abstract: The use of one or more compounds chosen from the compounds of the formulae Ia and Ib the physiologically compatible salts of the compounds of the formulae Ia and Ib and the stereoisomeric forms of the compounds of the formulae Ia and Ib, where R1, R2, R3, R4 and n have the meanings given in claim 1, for the preparation of a cosmetic formulation is advantageously suitable, e.g., for protecting cells, proteins and/or biomembranes of the human skin, for protecting the microflora of the human skin, and/or for stabilizing the skin barrier.

Abstract: The present invention provides novel emulsion formulations which comprise oil bodies. The invention also provides a method for preparing the emulsions and the use of the emulsions in products for topical application to the skin. The products are very mild to the skin and may be easily formulated into a wide variety of personal care and dermatological products.

Abstract: Novel compounds having a formula selected from the group consisting of wherein the substituents are defined as in the specification which are intermediates for the production of vinyl compounds having a remarkable anti-estrogenic and anti-proliferative activity.

Abstract: The invention relates to an aerosol container for pharmaceutically active aerosols that are to be administered in predetermined amounts and that are supplied in the container in the form of a suspension, the suspension also comprising, in addition to a pharmaceutically active substance, at least a propellant gas. The aerosol container has a metering valve that comprises a metering chamber and a valve stem. In a first position of the valve stem, the metering chamber is in communication with the interior of the container and has been filled with a predetermined amount of the aerosol. In a second position of the valve stem, the amount of aerosol disposed in the metering chamber is released. The propellant gas is an alternative propellant gas that is free of fluorochlorohydrocarbons, preferably a propellant gas that comprises only fluorohydrocarbons, and the inner wall of the container is coated with a plastics coating.

Abstract: The present invention is directed to a novel enteric-coated oral dosage form of a risedronate active ingredient comprised of a safe and effective amount of a pharmaceutical compostion which is comprised of a risedronate active ingredient and pharmaceutically-acceptable excipients. Said dosage forms prohibit the exposure of the risedronate active ingredient to the epithelial and mucosal tissues of the buccal cavity, pharynx, esophagus, and stomach and thereby protects said tissues from erosion, ulceration or other like irritation. Accordingly, the said dosage forms effect the delivery to the lower intestinal tract of said human or other mammal of a safe and effective amount of the risedronate active ingredient, and substantially alleviate the esophagitis or esophageal irritation which sometimes accompanies the oral administration of risedronate active ingredients.

Abstract: A polymerized hydrogel composition and applicator for hydrating or dehydrating a surface, particularly a dermatological surface, to which it is applied and a method for forming the composition. The composition is comprised of a mixture of two polymerizable materials, a two-part redox catalyst system and a two-part polymerization medium. The percentage by weight of each element in the composition may be varied within stated percentage ranges. The rate at which hydration or dehydration occurs may be controllably altered by varying the percentages of certain of the composition elements. The applicator includes a thermoplastic center section and two reservoir sections each having a reservoir storage area for holding moisture and/or medicaments. The composition is mechanically bonded onto each of the reservoir sections and then hydrated. The applicator is designed for insertion into a human mouth after hydration and is used for treating xerostomia.

Abstract: A novel oral pharmaceutical composition in the form of a stable flocculated suspension in water is described as comprising: megestrol acetate; at least one compound selected from the group consisting of polyethylene glycol, propylene glycol, glycerol, and sorbitol; and a surfactant, wherein polysorbate and polyethylene glycol are not simultaneously present.

Abstract: This application relates to a fibre structure which has, on the fibre surface, a complex oxide comprising titanium and silicon, plus a binder. In particular, it relates to a fibre structure which preferably has, on the fibre structure, a complex oxide comprising titanium and silicon, and at least one type of binder selected from alkyl silicate resins, other silicone resins and fluororesins, and it provides a fibre structure having durable deodorant properties, antibacterial properties, antifungal properties or antisoiling properties.

Abstract: A novel silicone gum and the use of a silicone gum such as diphenyldimethicone dissolved in a silicone oil for making a cosmetic of pharmaceutical compositions, particularly dermatological compositions, containing a fatty phase. Anb exemplary silicone oil is phenyltrimethicone. Also contemplated is the preparation of a cosmetic or pharmaceutical composition for skin care, in particular for the face or the body or for hair care.

Abstract: The invention relates to a ready-to-use binary gaseous mixture containing 63.1 to 69.9% by volume of helium and the remainder being oxygen, preferably a mixture of 65% of helium and of 35% of oxygen, and its use in the treatment of asthma, of obstructive bronchopneumopathies and the like. Such a gaseous mixture can be used as a vector or propellant gas for medicinal aerosols, in particular aerosols containing a therapeutically effective substance chosen from &bgr;2-mimetics, corticoids and anticholinergics.